ghk-cu immunogenicity antibodies neutralizing Brasil Anti-HGF Neutralizing Antibody ChimeraMAb ,

What the Evidence Actually Supports Its worth being precise about the state of evidence, because the gap between preclinical research and proven human clinical outcomes is significant in this area: Strong preclinical evidence: Hundreds of cell culture and animal studies demonstrate GHK-Cus biological activity across multiple pathways Moderate clinical evidence for topical applications: Several controlled human trials support skin benefits of topical GHK-Cu formulations Limited human evidence for systemic effects: The more dramatic claims tissue regeneration, gene expression reset, anti-aging effects throughout the body are largely supported by in vitro and animal data without the controlled human trials required to confirm efficacy and safety The scientific communitys interest in GHK-Cu is well-founded

The federation protocol can enable this by allowing the IdP to provide a link to an API with the record that represents the subscriber as well as a credential that allows limited access to this API

The burden of proof rests with the provider to demonstrate services rendered match the claim submitted

PMID 34404945